Free tool
Cell therapy stocks
We cover 3 companies grouped under the Cell therapy theme. The median market value in the group is $2.23B. Across the group, the median move over the past trading day is +1.91%. Price change over the past year runs from −45.5% to +6.8% across the middle 80 percent of the group, with a median of −3.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
3 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | 2.40 AUD | +16.26% | −13.54% | −3.82% | Aug 27, 2026 |
| MESO | Mesoblast Limited | $17.19 | +18.06% | −5.34% | +9.42% | Aug 27, 2026 |
| 4592.T | SanBio Company Limited | 1,024.00 JPY | +10.58% | −37.45% | −55.90% | Sep 14, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.